The present invention relates to the amyloid beta peptide (Aβ) and more specifically to antibodies binding to Aβ protofibrils and their use in therapy and/or prophylactic treatment of Alzheimer's disease and other disorders associated with Aβ protein aggregation. Further the invention may relate to diagnosis of such diseases as well as monitoring of disease progression by use of the antibodies of the invention. Further, the invention may relate to veterinary use of the antibodies of the invention.
